No Data
No Data
Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook
Exagen Outperforms: A Strong Buy on Rising Revenues, Margins, and Innovative Growth Prospects
Earnings Call Summary | Exagen(XGN.US) Q1 2024 Earnings Conference
The following is a summary of the Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript:Financial Performance:Exagen reported Q1 2024 total revenue of $14.4 million, driven by a strong increase in AVISE
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript
Exagen | 10-Q: Quarterly report
Exagen Q1 2024 GAAP EPS $(0.19) Beats $(0.36) Estimate, Sales $14.415M Beat $13.095M Estimate
Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.36) by 47.22 percent. This is a 56.82 percent increase over losses of $(0.44) per sh